Pharmacokinetics of Regorafenib by endogenous cortisol 6beta-hydroxylation clearance and potential of personalized use.

Trial Profile

Pharmacokinetics of Regorafenib by endogenous cortisol 6beta-hydroxylation clearance and potential of personalized use.

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 16 Mar 2018

At a glance

  • Drugs Regorafenib (Primary)
  • Indications Colorectal cancer; Gastrointestinal cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 12 Mar 2018 Status changed from recruiting to active, no longer recruiting.
    • 11 Mar 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top